The Impact of Brexit and MDR on Manufacturers: Balancing MDR Compliance with UKCA Requirements

The United Kingdom’s exit from the European Union (Brexit) has, undoubtedly, brought about great regulatory challenges and substantial opportunity for medical device manufacturers.

While the EU’s Medical Device Regulation (MDR) **EU 2017/745** remains a key framework for medical devices within the European Union, the UK has implemented its own independent regulation UK MDR 2002, with the UK Conformity Assessed (UKCA) mark as the primary requirement for market access in Great Britain (England, Scotland, and Wales).

This dual framework requires that manufacturers strategically navigate toward medical devices that wish to be marketed in both regions. We will subsequently examine how Brexit has affected MDR compliance and the steps that manufacturers need to take to be in congruence with the new UKCA.

Differentiating Regulatory Pathways: CE vs. UKCA

Insisting on compliance to the level of detailed requirements to further enhance safety and performance of the devices, the European Union Medical Device Regulation (MDR) lays down new requirements. It requires comprehensive clinical evidence, stringent post-market surveillance, and robust safety measures for medical devices.

All medical devices that would be sold in the European Economic Area (EEA) shall bear the CE mark affixed to them as evidence of conformity with the MDR’s regulatory requirements.

The aim of the above is to assure that devices are meeting safety and performance standards before being made available to patients and healthcare professionals.

Post-Brexit Navigation- After Brexit, the United Kingdom introduced the **UKCA** (UK Conformity Assessed) marking system, which applies to most goods, including medical devices, intended for the British market.

Despite originally adhering to EU regulations, it is progressively establishing an independent regulatory framework supervised by the Medicines and Healthcare Products Regulatory Agency (MHRA).

The UKCA mark supersedes the CE mark for devices sold in Great Britain; however, Northern Ireland continues to apply EU laws under the Northern Ireland Protocol, so use of the CE mark or UKNI marking is required for devices sold in that region.

Notably, medical devices certified under the EU MDR may continue to be placed on the British market until June 30, 2030, depending on device type and classification, provided the certification remains valid. Manufacturers have time to adjust to the changing UK-specific standards during this transitional phase.

Implications for Manufacturers

1. Under the Medical Device Regulation (MDR), manufacturers must collaborate with EU Notified Bodies to obtain CE marking for their products, which certifies conformity with EU regulatory requirements. Similarly, for each product covered by UKCA marking, manufacturers must work with UK Notified Bodies to meet the standards set by UK regulations.

2. Manufacturers seeking entry to the European Union and United Kingdom markets must navigate dual compliance requirements by adhering to the EU Medical Device Regulation (MDR) and the UKCA requirements for Britain.

3. For Distribution of medical devices in both the European Union and the United Kingdom products must display both the CE mark and the UKCA mark on labels to demonstrate conformity with the regulatory standards of each region.

4. Medical Device Regulation (MDR) mandates rigorous post-market surveillance and vigilance activities Likewise, the United Kingdom market, the Medicines and Healthcare products Regulatory Agency (MHRA) enforces comparable but distinct obligations i.e. reporting adverse incidents and undertaking field safety corrective actions to address potential risks.

Strategies for Navigating Dual Compliance

1. It is crucial to actively engage with both EU Notified Bodies and UK Approved Bodies to ensure smooth, hassle-free certification processes. Devices certified by EU Notified Bodies cannot automatically undergo a transition to UKCA marking unless they are evaluated by a UK Notified Body. These differences emphasize the importance of manufacturers’ navigating both systems carefully to ensure market access within the respective regions.

2. To streamline regulatory processes, manufacturers should maintain separate sets of technical documentation to meet the peculiar regulatory standards of each region. Manufacturers have to undergo two separate conformity assessment procedures to assure that their products meet those criteria established by each of the regulatory frameworks in safety, performance, and labeling. These dual obligations are necessary for manufacturers to gain market access and maintain compliance in both regions.

3. It is important to update labeling and marketing strategies for the sustenance of compliance in various regions. Region-specific labeling would be developed by manufacturers incorporating such conformity marks as the CE mark for the EU and the UKCA mark for Great Britain, together with appropriate symbols and updating regulatory information. It is equally important to communicate compliance information clearly to distributors and end-users to ensure transparency and trust. Such an approach will meet regulatory requirements while strengthening positioning in the marketplace and bolstering trust among customers

4. Manufacturers should develop PMS systems that are robust enough to align requirements of both the EU MDR and the UKCA legal frameworks. Such frameworks would effectively monitor devices when performed, gather real-life data, and identify safety issues that may arise. Proactive response to regulatory feedback and managing adverse event reporting are also critical to sustaining compliance and ensuring patient safety. This sort of proactiveness would not only leave risks at bay, but it would also reinforce the reliability and integrity of the manufacturer’s products in the marketplace.

Conclusion

Brexit has brought significant changes in the regulatory landscape for medical devices, and it has become imperative for manufacturers to navigate the complexities of MDR and UKCA compliance.

Although the extended transition timelines offer temporary relief, careful planning and investment in regulatory processes are crucial for long-term market access. By aligning strategies across both EU and UK frameworks, manufacturers can ensure compliance, minimize disruptions, and capitalize on opportunities in these Strategic and critical markets.

Contact me at ks@i3cglobal.com for further information on the CE and UKCA marking processes, including regulatory requirements, conformity assessment procedures, and technical documentation.

Author

Kirti Salunke (M.Pharm)

Technical Expert-Medical Device